H2o is back, better than even last year, and there’s no shortage of medical products on offer to make the transition easier.
The latest news comes as doctors and researchers around the world are gearing up for the holidays, with the launch of new medicines on offer from a new company called H2opharmaceuticals.
The company’s founders are keen to emphasise that the products they’re launching are not intended to replace existing treatments.
“There is no substitute for a good healthcare system,” said Dr Peter Molloy, one of the company’s co-founders.
“The best way to manage COVID-19 is to be active, stay in good physical and mental health, and take care of your body and immune system.”
Molloy and his co-founder, Peter Legg, are part of a small group of experts and academics who are actively looking to help the healthcare system cope with the spread of the coronavirus.
They’ve been developing H2-A, H2OP, and H2A-T, the new formulations of drugs that will replace older, more expensive and often toxic medicines, as well as new products designed to improve outcomes for people with chronic illnesses like COPD.
H2opharma, which also has a research arm, is also developing new products that are designed to address a range of medical problems, including:Inflammatory bowel diseaseThe painkiller Cialis has seen a big surge in popularity in recent years, with users using it to treat severe back pain, as a painkiller for people who are overweight and obese, and for people suffering from chronic pain.
While this is generally a good thing, it can also be an issue for people experiencing chronic pain, with some people having to take Cialises for their own chronic pain treatment.
To help alleviate this, Molloys team developed H2op, a new formulation of the painkiller that contains a new molecule that helps block the activity of an enzyme in the digestive tract that can lead to inflammation.
Molloys said that when he started looking into this molecule, he saw a compound that was “about as safe as a aspirin”.
“It is a combination of two drugs that have been in the market for a long time, one that is a non-steroidal anti-inflammatory drug (NSAID) and the other is a steroid that can inhibit the growth of tumor cells.”
“When you look at the molecule that is in Cialised, it is actually about the same size as aspirin, so it is in the same class as other NSAIDs and steroids, and it is less likely to cause side effects,” he said.
“So, in terms of safety, it’s an absolute winner.”
Molls and Legg are looking at the H2OBiol drug, HCl.
The HCl is also a non steroidal, non-inflammatory and non-toxic, and is available in pill and powder form.
It can be used to treat symptoms of COVID, but it is also used to help treat inflammation, which can be caused by various things, including certain bacteria in the gut.
“One of the things we were really excited about is that we can now make a pill that will help people manage inflammation without any side effects, and then, for people that have COVID and are suffering from inflammation, we can do a pill for those people,” Mollays said.
It was a tough decision to take, but Molloya said that it was the right one.
“We were really looking at a few different options, and ultimately, the choice was between these two options,” he told Engadgett.
“So, the HCl pill, that is the same molecule as aspirin and the HCL pill, we decided to go with the Hcl.”
He said the pill will be available to the public soon, and said that he would have to be cautious about it.
“When I look at this molecule and I look around, I see that it’s about the size of a pill and that it doesn’t seem like it will be very effective, so I’m not sure if I should go ahead and take it,” he added.
While the company is not looking to replace expensive or toxic medicines for its patients, its products are not meant to replace those, as there is no replacement for good healthcare.
“It’s important that we not make the wrong choice and try to change the system,” he explained.
“H2O was not meant for us.
So, the next step would be to see what is the right drug to go after and make the right choices, and what we can provide for our patients.”